Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

Blood thinners are a class of medications that help prevent blot clots from forming ... Some of the commonly prescribed direct oral anticoagulants are Eliquis (apixaban), Xarelto (rivaroxaban), and ...

Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, partially offset by a decline in demand for Sprycel due to generic erosion. Eliquis sales reached $3 billion from $2. ...